<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Eltrombopag is a nonpeptidyl thrombopoietin receptor <z:chebi fb="4" ids="48705">agonist</z:chebi> </plain></SENT>
<SENT sid="1" pm="."><plain>We evaluated the ex vivo effect of eltrombopag on megakaryopoiesis of patients with lower risk <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (MDSs) </plain></SENT>
<SENT sid="2" pm="."><plain>At a concentration of 0.1Î¼g/mL, eltrombopag resulted in a significant increase in the number of megakaryocytic colonies in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients and healthy controls compared to baseline </plain></SENT>
<SENT sid="3" pm="."><plain>This dose of eltrombopag did not exert any significant change in the proliferation rate or the survival characteristics of patient CD34(+) cells that might clinically imply an unfavorable effect on patients' outcome </plain></SENT>
<SENT sid="4" pm="."><plain>These encouraging preclinical data support the rationale of using eltrombopag in the clinic for alleviation of <z:hpo ids='HP_0001873'>thrombocytopenia</z:hpo> in lower risk <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients </plain></SENT>
</text></document>